Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implementing and Optimizing Biosimilar Use at Mayo Clinic.

Chelsee J Jensen1, Eric M Tichy1, Mary B Lempke1

  • 1Pharmacy Supply Solutions, Mayo Clinic, Rochester, MN.

Mayo Clinic Proceedings
|March 26, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National trends in prescription drug expenditures and projections for 2026.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and Sales.

American journal of hematology·2026
Same author

Patient Characteristics, Treatment Patterns, and Outcomes in Unresectable Hepatocellular Carcinoma Treated with First-Line Systemic Therapy in the United States.

Cancers·2025
Same author

The three-fer: How biosimilars reduce cost, expand access, and improve margin.

Journal of the American Pharmacists Association : JAPhA·2025
Same author

Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?

JCO oncology practice·2025
Same author

Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab: Highlights From Pharmacists' Perspectives.

Journal of the advanced practitioner in oncology·2025
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

A multidisciplinary team improved biosimilar adoption across 5 biologics at Mayo Clinic, resulting in significant cost savings. This initiative enhanced the use of biosimilars, benefiting patient care and healthcare economics.

Area of Science:

  • Pharmacoeconomics and Health Outcomes Research
  • Clinical Pharmacy and Practice
  • Biopharmaceutical Sciences

Background:

  • Biosimilar adoption is crucial for reducing healthcare costs and increasing patient access to biologic therapies.
  • Implementing biosimilars requires strategic planning involving multidisciplinary teams and optimized healthcare systems.
  • Mayo Clinic sought to enhance biosimilar uptake for key biologics to improve cost-effectiveness.

Purpose of the Study:

  • To evaluate the impact of a multidisciplinary team, pharmacist-led therapeutic interchange, and EHR optimization on biosimilar adoption.
  • To assess changes in the utilization of biosimilars for bevacizumab, epoetin alfa, filgrastim, rituximab, and trastuzumab.
  • To quantify the financial savings associated with increased biosimilar use.

Main Methods:

Related Experiment Videos

  • A retrospective analysis of pharmaceutical wholesale purchase data for 5 reference products and their biosimilars.
  • Comparison of purchasing data from September 1, 2019–August 31, 2020, with data from September 1, 2020–August 31, 2021.
  • Implementation of formulary decisions for biosimilars across 5 biologics starting September 1, 2020, with tracking of drug units and expenditures.

Main Results:

  • Significant increases in the adoption of formulary-preferred biosimilars were observed, ranging from 63% to 80% across the 5 biologics.
  • Bevacizumab, epoetin alfa, filgrastim, rituximab, and trastuzumab showed substantial gains in biosimilar utilization.
  • Total pharmaceutical line item savings reached $23.1 million within the 12-month postimplementation period.

Conclusions:

  • The formation of a multidisciplinary team and strategic implementation of formulary-preferred biosimilars effectively drove biosimilar adoption.
  • The initiative resulted in considerable pharmaceutical line item savings, demonstrating the economic benefits of biosimilar utilization.
  • This approach provides a scalable model for enhancing biosimilar uptake in large healthcare systems.